The CareStart G6PD kit (CSG; AccessBio Inc, New Jersey) requires no specialized training, equipment, cold chain, or controlled temperature

setting. A result is rendered within 10 minutes. The kit sells for $1.50 per test. We reasoned that practical point-of-care qualitative screening for G6PD by CSG should be noninferior to the FST in red blood cells (RBCs) exhibiting variable levels of residual G6PD activity after being incubated with the G6PD inhibitor CuCl. After optimizing that inhibition, we designed check details and executed a series of double-blinded experiments to assess the noninferiority of CSG to FST using simulated G6PD-deficient RBCs for both hemizygous and heterozygous states. We aimed this work at generating the evidence

needed to inform decisions for investment in more ambitious evaluations in patients in rural tropical settings. The quantitative assay for erythrocytic G6PD activity in hemolysate was performed using the commercial kit from Trinity Biotech (Ireland) as catalog number (cat#) 345-B. The manufacturer’s Alpelisib cost instructions were followed. In brief, substrate of glucose-6-phosphate and cofactor nicotinamide adenine diphosphate, NADP+, was reconstituted with sterile double-distilled water and 2 mL added to 1 mL of hemolysate reaction buffer (provided by the manufacturer). Then, 10 μL of whole blood collected in acid citrate dextrose (ACD) tubes (BD Vacutainer ACD Solution A; Becton-Dickinson) was added to the 3 mL mixture. The tube was incubated at 30°C for 5 minutes and its absorbance at 340 nm wavelength was measured on an ultraviolet spectrophotometer Thiamet G (Biowave II; Biochrome) and recorded as “initial” absorbance optical density. An additional 5 minutes in the 30°C water bath was followed by another absorbance measurement recorded

as “final.” Hemoglobin levels on all venous blood samples were measured using a clinical blood analyzer (Abbott Cell Dyne CD1700). These values were applied to calculate the international units of enzyme activity per gram hemoglobin as per the manufacturer’s instructions. In accordance with the Code of Ethics of the World Medical Association expressed in the Declaration of Helsinki, each collection of blood in these experiments was done with the signed, informed consent of the 2 G6PD normal subjects involved under a protocol for such collections that was reviewed and approved by the Ethics Review Board of the Eijkman Institute for Molecular Biology. Copper inhibits G6PD activity,19 but no work yet described optimized inhibition in intact RBC suspensions.